Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study

NCT00799656 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00799656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00799656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2008
Completion date
September 30, 2009
Enrollment
62 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pain